|RAS046-C01||Pre-coated SARS-CoV-2 Spike Trimer Microplate||1 plate|
|RAS046-C02||Anti-SARS-CoV-2 Antibody (Control, Monkey IgG)||100 μL|
|RAS046-C03||Positive Control||100 μL|
|RAS046-C04||Negative Control||100 μL|
|RAS046-C05||HRP-Goat anti-Monkey IgG||100 μL|
|RAS046-C06||10×Washing Buffer||50 mL|
|RAS046-C07||Dilution Buffer||50 mL|
|RAS046-C08||Substrate Solution||12 mL|
|RAS046-C09||Stop Solution||7 mL|
The unopened kit is stable for at least 1 year from the date of manufacture if stored at 2°C to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.
Your experiment will include 4 simple steps:
a) Add your sample to the plate. The samples and Control sample are diluted by Dilution Buffer.
b) Add diluted Secondary antibody HRP-Anti-Goat anti monkey IgG to the plate. The Secondary antibody is diluted by Dilution Buffer.
c) Wash the plate and add TMB or other colorimetric HRP substrate.
d) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Detection of Monoclonal Anti-SARS-CoV-2 Antibody, Monkey IgG titer by Indirect-ELISA Assay.
Immobilized SARS-CoV-2 Spike Trimer at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Monkey IgG in 1:50 monkey serum. Detection was performed using HRP-Goat anti-Monkey IgG antibody with sensitivity of 98 ng/mL (QC tested).
Price(USD) : $580.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.